Printed from Voxsanity (voxsanity.com.au) — NCT06962189 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Lung Cancer
Phase 2 Lung Cancer Trial, Not Yet Recruiting
NCT06962189
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who are willing to take part voluntarily and agree to sign a consent form, including consent for testing of collected biological samples.
- People who have been confirmed through tissue or cell testing to have non-small cell lung cancer (NSCLC) and have not yet received any cancer treatment, including medications or local treatments.
- People with unresectable stage IIIB or IIIC NSCLC (cancer that cannot currently be surgically removed) where a specialist team has assessed that surgical removal of the main lung tumour may become possible after initial chemotherapy and immunotherapy treatment, and that any spread to certain lymph nodes could be treated with radiation.
- People aged 18 to 75 years, of any gender.
- People with a good general physical condition, rated 0 or 1 on a standard performance scale (meaning fully active or able to carry out light activity).
- People with at least one tumour that can be measured using standard imaging criteria (RECIST v1.1).
- People whose suspicious lymph nodes in the chest area have been checked through procedures such as ultrasound-guided biopsy, keyhole surgery, or mediastinoscopy, where technically possible.
- People whose lung function (measured by breathing tests) has been assessed by a specialist team as adequate to safely undergo planned lung surgery.
- People without other health conditions that would make surgery too risky.
- People whose blood test results within the 14 days before joining the trial show that their organs are working adequately across a range of measures including blood counts, liver function, kidney function, and thyroid function (confirm specific values with the trial site).
- Women who have not been surgically sterilised or gone through menopause must use contraception during the study and for 3 months after treatment ends, must have a negative pregnancy test within 72 hours before joining, and must not be breastfeeding; male participants with partners who could become pregnant must also use effective contraception during the trial and for 3 months after the last dose.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose NSCLC has specific gene changes (driver mutations) such as EGFR, ALK, or ROS1.
- People who have previously been treated with certain immunotherapy drugs that target pathways involving PD-1, PD-L1, PD-L2, or CTLA-4.
- People who have had another cancer in the past 3 years, except for certain fully treated skin cancers (basal cell carcinoma) or pre-cancerous cervical conditions (cervical carcinoma in situ).
- People with active hepatitis B or C that has not responded well to antiviral treatment.
- People with currently active autoimmune diseases or a history of certain autoimmune conditions such as autoimmune hepatitis, lung inflammation, eye inflammation, bowel inflammation, or certain thyroid, kidney, or blood vessel conditions (vitiligo and childhood asthma that resolved on its own are generally permitted; asthma requiring ongoing medication is not).
- People currently taking immune-suppressing medications or corticosteroids at a dose greater than the equivalent of 10 mg per day of prednisone within the 2 weeks before joining.
- People with poorly controlled high blood pressure or serious heart conditions such as significant heart failure, unstable chest pain, a heart attack within the past year, certain heart rhythm problems requiring treatment, or an abnormal heart electrical reading above set thresholds.
- People with blood clotting problems, a tendency to bleed, or who are currently on clot-dissolving or blood-thinning medications (low-dose aspirin or preventive low-molecular-weight heparin may be permitted — confirm with trial site).
- People who have had a blood clot event such as a stroke, mini-stroke, deep vein thrombosis, or pulmonary embolism within the past 6 months.
- People with inherited or acquired bleeding or clotting disorders such as haemophilia or thrombocytopenia.
- People whose urine tests show significant levels of protein, confirmed by a 24-hour urine collection showing more than 1.0 g of protein.
- People with an active infection, an unexplained fever of 38.5°C or higher in the 7 days before starting treatment, or a white blood cell count that is too high at the start of the trial.
- People with immune system deficiencies, whether from birth or acquired (such as HIV infection).
- People where the investigating doctor determines that other factors — such as substance use, serious health conditions, mental health conditions, or circumstances affecting their ability to follow the study requirements — could affect their safety or the study's results.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Contact this trial
Phone: +86-18767186629
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Not Yet Recruiting
Phase
Phase 2
Sponsor
Zhejiang University
Registry
ClinicalTrials.gov
Start date
15 May 2025
Est. completion
31 December 2027
Primary endpoints
conversion rate; 1-y PFS
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.